COVID-19 Burden and Risk Among People With HIV

Deborah L. Jones, PhD, MEd, Kristiana E. Morgan, BS, Paola C Martinez, BS, Violeta J. Rodriguez, MSEd, MS, Andres Vazquez, MS, Patricia D. Raccamarich, MD, and Maria L. Alcaide, MD

Background: This study evaluated COVID-19 risk and burden among people with HIV (PWH) in a US city with high rates of HIV and SARS-CoV-2 transmissions and examined the interrelationship between psychosocial factors and COVID-19 risk and burden.

Setting: Participants were drawn from an existing consent to contact database of PWH. Database candidates were PWH, adults older than 18 years, people who had received HIV care at the University of Miami HIV clinics, people who spoke English or Spanish, and people who had agreed to be contacted for future research.

Methods: An adapted version of the Multicenter AIDS Cohort Study/Women’s Interagency HIV Study Combined Cohort Study COVID-19 survey was telephonically administered, requiring 15–30 minutes.

Results: Psychological stress was a predictor of COVID-19 burden (financial and social burden) and COVID-19 risk (health factors associated with an increased risk of severe health outcomes due to infection with COVID-19). Having a history of traumatic events was associated with increased COVID-19 risk, and stress was associated with increased COVID-19 burden and COVID-19 risk.

Conclusions: Overall, results suggest that the intersection of the HIV and COVID-19 pandemics may be most profound among those who have experienced traumatic events; and traumatic events may be associated with heightened vigilance regarding illness and infection.

Key Words: COVID-19, HIV, trauma, depression, stress

INTRODUCTION

Since first declared a pandemic on March 11, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 of COVID-19) has created a tremendous burden on the general population, with more than 30 million cases and more than 1 million deaths worldwide. Individuals aged 60 years and older and those with asthma, chronic lung, kidney or liver disease, diabetes, cardiovascular conditions, or obesity are more likely to experience COVID-19-related morbidity and mortality. In addition, those with immunocompromising conditions such as cancer and HIV with low CD4 counts or without treatment are also at increased likelihood. Racialized communities are often at disproportionate risk of severe illness due to COVID-19 caused by multiple comorbidities, and non-HIV-related comorbidities such as diabetes and hypertension are more frequent among people with HIV (PWH), with even higher rates among older PWH.

In addition to disease burden, lifestyle challenges associated with COVID-19, for example, shelter-in-place orders, home quarantine, and social distancing have contributed to profound social, behavioral, and financial disruption among the general population, especially among those at risk of more severe health outcomes. Disruption of resources (eg, health care access, commodity shortages, change in childcare, loss of income, or employment), social isolation, and confusing public health information have also contributed to increased psychosocial stress.

Early research on the effects of COVID-19 highlighted increased levels of anxiety and depressive symptoms; risk factors associated with depression and anxiety have included reduced income, having a chronic disease, or having family member with chronic disease, all factors more frequent during the pandemic.

Previous research found that stress negatively impacts physical and emotional health and health behaviors and may be higher among PWH, many of whom have heightened health risks due to comorbidities and are from racial and sexual minorities and living in poverty. As a result, PWH may have greater anxiety associated with COVID-19, which may also reduce quality of life.

Although PWH with high CD4 counts and on effective antiretroviral treatment do not seem to be at greater risk of COVID-19 transmission, it is their non-HIV-related comorbidities that create a greater and realistic threat of contracting and experiencing complications from COVID-19. In addition, PWH may face greater psychosocial burden—living with HIV and with the mandates arising from...
efforts to control the pandemic—including intimate partner violence, stigma, isolation, discrimination, and challenges to obtaining treatment. Traumatic events, in particular, can increase the likelihood of stress and depression, which compounded may be a risk factor for increased mortality. 

Existing health disparities, psychosocial pressures, health concerns, and psychological distress may exacerbate the overall risk and burden associated with COVID-19 among PWH. This study evaluated the burden and risk of overall risk and burden associated with COVID-19 among PWH, and explored the impact of COVID-19-related stress among PWH in Miami. We hypothesized that psychosocial factors, such as having a history of traumatic events, stress, and depression, likely predicts the burden of COVID-19 among PWH.

METHODS

Participants and Procedures

Participants were drawn from an existing consent to contact database of PWH at the University of Miami. Candidates enrolled in the database were PWH older than 18 years who had received HIV care at the University of Miami HIV clinics, spoke English or Spanish, had participated on the Miami Center for AIDS Research (CFAR)/Center for HIV Research and Mental Health (CHARM) patient database registry study, and agreed to be contacted for future research. 

Candidates from the database were contacted through text message and 2 consecutive phone calls. Data for this cross-sectional study were collected from participants from May to August 2020 and combined with existing patient registry data. Interview staff described the nature of the study, and of those contacted, N = 200 participants provided verbal consent and were enrolled in the current study. An adapted version of the MACS/WIHS Combined Cohort Study COVID-19 survey developed in response to the COVID-19 pandemic was verbally administered by telephone, requiring 15–30 minutes. Participants completed the survey in their preferred language, English or Spanish, and survey data were collected using REDCap licensed with the University of Miami. Participants were compensated US$25 on completion of the survey.

Variables/Measures

Database Variables

The following variables and surveys were abstracted from the existing participant database:

Demographics

Participants completed a demographic questionnaire including age, sex at birth, race, employment, average monthly income, and living/housing situation.

Trauma/History of Traumatic Events

The Brief Trauma Questionnaire was used to examine exposure to 10 potentially traumatic events, including participation in a war zone, serious car accident, major natural or technological disaster, life-threatening illness, physical abuse in childhood, physical assault, unwanted sexual contact, other situations in which respondent was seriously injured or feared being seriously injured or killed, violent death of a close friend or family member, and witnessing a situation in which someone was seriously injured or killed. Participants indicated whether they had experienced traumatic events and their assessment of how dangerous these events were. In addition, respondents reported whether they had been injured. Total scores for this scale ranged from 0 to 16.

Childhood and Adult Physical and Sexual Abuse

Participants reported the occurrence of childhood and adult physical and sexual abuse through 4 questions: As a child, were you ever beaten, physically attacked, or physically abused? As a child, were you ever sexually attacked, raped, or sexually abused? As an adult, have you ever been beaten, physically attacked, or physically abused? As an adult, have you ever been sexually attacked, raped, or sexually abused? Answers to these items were summed, and the total score was used in analyses. Internal consistency in this sample was adequate (α = 0.73).

Posttraumatic Stress Disorder Symptoms

The Primary Care Posttraumatic Stress Disorder (PTSD) Screen is a 4-item screening questionnaire intended to assess symptoms of PTSD, including nightmares, avoidance, hypervigilance, and detachment. Answers to these items were summed, and the total score was used in analyses. Internal consistency in this sample was acceptable (α = 0.82).

Sleep Difficulties

The 7-item Insomnia Severity Index was used to measure sleep difficulties. The Insomnia Severity Index has been shown to be a sensitive and specific measure of insomnia. Internal consistency in this sample was acceptable (α = 0.84).

Substance Use

Drug use was assessed using the Drug Abuse Screening Test-10 (DAST-10, Spanish), which measures problems related to drug use, excluding alcohol and tobacco. A total DAST-10 score was used in analyses (α = 0.89).

MACS/WIHS Combined Cohort Study COVID-19 Survey

The MACS/WIHS Combined Cohort Study survey, developed in response to the COVID-19 pandemic, consisted of 10 sections used to assess sociodemographic information, household and tobacco use, risk factors for SARS-CoV-2 acquisition (eg, travel and contact to infected individuals), COVID-19 signs and symptoms, COVID-19 contingency
behaviors, medical history and medications for HIV and non-HIV comorbidities, COVID-19 contact risk, testing and treatment, disruption to resources, abuse and psychosocial factors. Psychological factors assessed in the survey were drawn from existing instruments and adapted for the survey to reflect the period of the pandemic. From this survey, the following measures were used:

COVID-19 Burden

COVID-19 burden was a total sum score of items regarding COVID-19 (e.g., “Have you tested positive for COVID-19?”). COVID-19 symptoms (e.g., fever, chills, and muscle aches), having suspect COVID-19, income loss, childcare loss, loss of other sources of income, loss of housing, being unable to obtain medications (including ART) or healthcare, or being unable to receive substance use or mental health treatment. Sum scores are widely used to study the accumulation of burden and risk.\(^{32–34}\)

COVID-19 Risk

COVID-19 risk was defined as a sum score of endorsing having cardiovascular, renal, neurological, gastrointestinal, pulmonary condition, or an active malignancy or immunosuppression.

Loneliness

A 3-item University of California, Los Angeles Loneliness Scale was used to measure loneliness.\(^{35}\) Participants are asked to report on feelings of lack of companionship, feeling left out, or being isolated from others. Items were summed, and the total sum score was used. Internal consistency in this sample was acceptable (\(\alpha = 0.74\)).

Stress

To assess stress, the four-item Perceived Stress Scale\(^{36}\) was used. Three items are reverse coded and then summed. Internal consistency in this sample was adequate (\(\alpha = 0.78\)).

Depressive Symptoms

The Center for Epidemiologic Studies Depression Scale\(^{37}\) was used to measure depressive symptoms. Respondents are asked to rate the frequency of each mood or symptom during the past 2 weeks on a 4-point scale. The reliability coefficient for this scale was in the acceptable range (\(\alpha = 0.88\)).

Analytic Plan

Descriptive analyses included mean and SD for key study variables. Path analyses were used to test 3 different linear regression models. Model 1 included history of traumatic events, childhood and adult physical and sexual abuse, PTSD symptoms, loneliness and stress as predictors of COVID-19 burden, and COVID-19 risk. Following model 1, model 2 tested stress and depressive symptoms as mediators in the association between history of trauma and COVID-19 burden. Model 3 included COVID-19 burden and COVID-19 risk as predictors of depressive symptoms, sleep problems, and substance use. Descriptive analyses were conducted in SPSS v26, whereas path analyses were conducted in Mplus 8.4, which uses maximum likelihood estimation to estimate regression models. Maximum likelihood is robust to deviations from normality as well as outliers.\(^{38}\) A threshold of \(P < 0.05\) was used to establish statistical significance.

RESULTS

Demographic Characteristics of Participants

On average, participants were aged 54.56 (SD = 10.86) years, and 57% of participants were women. Two-thirds of participants (66%) were born in the United States, and 70% were Black/African American. Only 20% of participants were employed, and nearly half (48%) had a monthly income of $501–$1000. Further demographic information is described in Table 1. COVID-19 burden and risk are described in Table 2. COVID-19 burden and risk or history of traumatic events did not differ by sex (\(P = 0.862, P = 0.319, P = 0.053\), respectively). In addition, although COVID-19 burden and risk were associated with age (\(P = 0.241, P = 0.001\) and \(P = 0.060, P = 0.398\), respectively), traumatic events were not (\(P = -0.264, P < 0.001\)). Therefore, these variables were not controlled for in subsequent analyses.

### TABLE 1. Demographic Characteristics (N = 200)

| Variable                        | M (SD)       | N (%)       |
|---------------------------------|--------------|-------------|
| **Age**                         | 53.56 (10.86)| Range: 26, 75 |
|                                 | Median:      | 55          |
| Sex                             |              |             |
| Male                            | 87 (43.5)    |             |
| Female                          | 113 (56.5)   |             |
| Born in the United States       | 132 (66.0)   |             |
| Race                            |              |             |
| Black/African American          | 140 (70.0)   |             |
| White                           | 47 (23.5)    |             |
| Asian                           | 1 (0.5)      |             |
| Native American                 | 3 (1.5)      |             |
| Other                           | 9 (4.5)      |             |
| Employed                        | 40 (20.0)    |             |
| Average monthly income          |              |             |
| $500 or less                    | 37 (18.5)    |             |
| $501–$1000                      | 95 (47.5)    |             |
| $1001–$1500                     | 24 (12.0)    |             |
| $1501–$2000                     | 17 (8.5)     |             |
| $2001–$2500                     | 9 (4.5)      |             |
| $2501–$3000                     | 5 (2.5)      |             |
| $3001–$6250                     | 12 (6.0)     |             |
| Living/housing situation        |              |             |
| Own house/apartment             | 153 (76.5)   |             |
| Parents’ house                  | 13 (6.5)     |             |
| Someone else’s house            | 29 (14.5)    |             |
| Rooming, boarding, or halfway   | 4 (2.0)      |             |
| On the street(s)                | 1 (0.5)      |             |

COVID-19 burden was calculated as the sum score of participants providing a “yes” response to the items above. Similarly, COVID-19 risk was calculated as the sum score of participants providing a “yes” response to the items above.
Model 1: History of Traumatic events, Childhood and Adult Physical and Sexual Abuse, PTSD Symptoms, Loneliness, and Stress Predicting COVID-19 Burden and Risk

Model 1 included history of traumatic event, childhood and adult physical and sexual abuse, PTSD symptoms, loneliness, and stress as predictors of COVID-19 burden and COVID-19 risk. History of traumatic events was associated with increased COVID-19 risk \(\beta = 0.230 \ (SE = 0.081), P = 0.004\), and stress was associated with increased COVID-19 burden \(\beta = 0.282 \ (SE = 0.081), P < 0.001\) and COVID-19 risk \(\beta = 0.169 \ (SE = 0.080), P = 0.035\). The full model is presented in Table 3.

Model 2: Stress and Depressive Symptoms as Mediators Between History of Traumatic Events and COVID-19 Burden

As a follow-up to model 1, model 2 tested stress and depressive symptoms as mediators in the association between history of traumatic events and COVID-19 burden. The total indirect effect of history of traumatic events on COVID-19 burden through stress and depressive symptoms was significant (total indirect effect = 0.091, \(SE = 0.027, P = 0.001\)). Examining the specific pathways, a history of trauma predicted COVID-19 burden through stress (indirect effect = 0.042, \(SE = 0.020, P = 0.040\)) and depressive symptoms (indirect effect = 0.049, \(SE = 0.022, P = 0.025\)). That is, both stress and depressive symptoms mediated the associations between history of trauma and COVID-19 burden. Given that model 2 is an extension of model 1, it is presented in the full model in Table 3.

Model 3: COVID-19 Burden and COVID-19 Risk Predicting Depressive Symptoms, Sleep Problems, and Substance Use

Model 3 examined COVID-19 burden and COVID-19 risk as predictors of depressive symptoms, sleep problems, and substance use in a path analysis. COVID-19 burden was associated with increased depressive symptoms \(\beta = 0.289 \ (SE = 0.064), P < 0.001\) and sleep difficulties \(\beta = 0.206 \ (SE = 0.066), P = 0.002\) per every SD increase in COVID-19 burden. COVID-19 risk was similarly associated with both increased depressive symptoms \(\beta = 0.184 \ (SE = 0.066), P = 0.005\) and sleep difficulties \(\beta = 0.244 \ (SE = 0.065), P < 0.001\) per every SD increase in COVID-19 risk. Neither COVID-19 burden nor risk was associated with substance use. The full path analysis is presented in Table 4.

### DISCUSSION

This study evaluated COVID-19 risk and burden among PWH in one of the cities with the highest numbers of HIV and SARS-CoV-2 transmissions in the United States and examined the interrelationship between psychosocial factors and COVID-19 risk and burden. Results indicate that psychological stress was a predictor of COVID-19 burden (financial and social burden) and COVID-19 risk (health factors associated with an increased risk of severe health outcomes due to COVID-19); and history of traumatic events was associated with increased COVID-19 risk. In addition, COVID-19 burden and COVID-19 risk were predictors of depression and sleep problems, but not substance use. Overall, results suggest that the intersection of the HIV and COVID-19 pandemics may be most profound among those who have experienced traumatic events because trauma may create a hypervigilant state with heightened vigilance regarding COVID-19. Having a history of traumatic events was associated with increased COVID-19 risk, and stress was associated with increased COVID-19 burden and COVID-19 risk. In a mediational model intended to examine pathways among these variables, having a history of traumatic events was associated with increased stress, which was in turn associated with greater COVID-19 burden. As a mediator, trauma explained the observed relationship of stress and depression with COVID-19 burden, such that stress and depression influenced COVID-19 burden through the trauma history.

Participants with a history of traumatic events were most likely to experience the negative impact of COVID-19

---

**TABLE 2. COVID-19 Burden and Risk (N = 200)**

| COVID-19 burden | N (%) |
|-----------------|-------|
| Test positive for COVID-19 | 7 (3.5) |
| COVID-19 symptoms | 11 (5.5) |
| Suspect COVID-19 infection | 7 (3.5) |
| COVID-19 impact | 93 (46.5) |
| Employment loss due to COVID-19 | 82 (41.0) |
| Childcare loss | 23 (11.5) |
| Financial loss | 17 (8.5) |
| Housing loss | 16 (8.0) |
| Unable to obtain medications | 19 (9.5) |
| Unable to obtain HIV medications | 15 (7.5) |
| Unable to afford medical care | 31 (15.5) |
| Health insurance loss | 9 (4.5) |
| Mental health treatment loss | 23 (11.5) |
| Substance use treatment loss | 25 (12.5) |
| COVID-19 risk |       |
| Hypertension | 103 (51.5) |
| Heart disease (eg. cardiomyopathy and coronary artery disease) | 20 (10.0) |
| Diabetes | 43 (21.5) |
| Renal disease | 7 (3.5) |
| Pulmonary disease | 39 (19.5) |
| Neurological conditions | 21 (10.5) |
| Gastrointestinal conditions | 9 (4.5) |
| Cancer | 15 (7.5) |
| History of transplant | 3 (1.5) |
| Rheumatological disease | 22 (11.0) |
| Pneumonia | 12 (6.0) |
| Former tobacco smoker | 21 (10.5) |
| Current tobacco smoker | 11 (5.5) |

COVID-19 burden was calculated as the sum score of participants providing a “yes” response to the items above. Similarly, COVID-19 risk was calculated as the sum score of participants providing a “yes” response to the items above.
TABLE 3. Model 1: History of Trauma, Childhood and Adult Physical and Sexual Abuse, PTSD Symptoms, Loneliness, and Stress Predicting COVID-19 Burden and Risk

| Outcome: COVID-19 risk | $\beta$ | SE | t   | P    |
|------------------------|--------|-----|-----|------|
| Childhood and adult physical and sexual abuse | 0.023 | 0.081 | 0.28 | 0.778 |
| Posttraumatic stress disorder symptoms | -0.043 | 0.080 | -0.54 | 0.592 |
| Loneliness | 0.128 | 0.080 | 1.61 | 0.108 |
| Stress | 0.169 | 0.080 | 2.12 | 0.035 |
| History of trauma/traumatic events | 0.230 | 0.081 | 2.85 | 0.004 |

Outcomes: COVID-19 burden

| Outcome: COVID-19 burden | $\beta$ | SE | t   | P    |
|--------------------------|--------|-----|-----|------|
| Childhood and adult physical and sexual abuse | 0.048 | 0.076 | 0.63 | 0.528 |
| Posttraumatic stress disorder symptoms | 0.082 | 0.078 | 1.05 | 0.295 |
| Loneliness | -0.045 | 0.082 | -0.55 | 0.580 |
| Stress | 0.282 | 0.081 | 3.51 | <0.001 |

Standardized coefficients are presented. Model 2 was based off Model 1.

TABLE 4. Model 3: COVID-19 Burden and COVID-19 Risk Predicting Depressive Symptoms, Sleep Problems, and Substance Use

| Outcome: depressive symptoms | $\beta$ | SE | t   | P    |
|-----------------------------|--------|-----|-----|------|
| COVID-19 risk | 0.184 | 0.066 | 2.81 | 0.005 |
| COVID-19 burden | 0.289 | 0.064 | 4.52 | <0.001 |

| Outcome: substance use | $\beta$ | SE | t   | P    |
|------------------------|--------|-----|-----|------|
| COVID-19 risk | 0.121 | 0.070 | 1.73 | 0.083 |
| COVID-19 burden | -0.112 | 0.070 | -1.60 | 0.11 |

| Outcome: sleep difficulties | $\beta$ | SE | t   | P    |
|----------------------------|--------|-----|-----|------|
| COVID-19 risk | 0.244 | 0.065 | 3.73 | <0.001 |
| COVID-19 burden | 0.206 | 0.066 | 3.12 | 0.002 |

Standardized coefficients are presented.
REFERENCES

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533–534.
2. CDC. People at Increased Risk for Severe Illness. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/certain-groups/hiv.html. Accessed September 20, 2020.
3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
4. Tai DB, Shah A, Doubeni CA, et al. The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States. Clin Infect Dis. 2020;72:703–706.
5. Rodriguez-Penney AT, Iadecollo JE, Riggio PK, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013;27:5–16.
6. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:91–92.
7. Guo Y, Cheng C, Zeng Y, et al. Mental health disorders and associated risk factors in quarantined adults during the COVID-19 outbreak in China: cross-sectional study. J Med Internet Res. 2020;22:e20328.
8. Pfefferbaum B, North CS. Mental health and the covid-19 pandemic. New En LG J Med. 2020;383:510–512.
9. Wang C, Pan R, Wan X, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17:1729.
10. Fitzpatrick KM, Harris C, Drawe G. Living in the midst of fear: depressive symptomatology among US adults during the COVID-19 pandemic. Depression Anxiety. 2020;37:957–964.
11. Krishnan S, Dunbar MS, Minnis AM, et al. Poverty, gender inequities, and women’s risk of human immunodeficiency virus/AIDS. Ann NY Acad Sci. 2008;1136:101–110.
12. Lebel S, Mutsaers B, Tomei C, et al. Health anxiety and illness-related fears across diverse chronic illnesses: a systematic review on conceptualization, measurement, prevalence, course, and correlates. PLoS One. 2015;10:e0234124.
13. Joenesen LE, Madsen KP, Holm L, et al. Diabetes and COVID-19: psychosocial consequences of the COVID-19 pandemic in people with diabetes in Denmark—what characterizes people with high levels of COVID-19-related worries? Diabet Med. 2020;37:1146–1154.
14. Vizcarra P, Pérez-Elias MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7:E554–E564.
15. Cooper T, Woodward B, Alom S, et al. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020;21:567–577.
16. Chenneville T, Gabbidon K, Hanson P, et al. The impact of COVID-19 on HIV treatment and research: a call to action. Int J Environ Res Public Health. 2020;17:4548.
17. Blanco JL, Ambrosioni J, García F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314–e316.
18. Mirzaei H, McFarland W, Karamouzian M, et al. COVID-19 among people living with HIV: a systematic review. AIDS Behav. 2020;11:1–8.
19. Rosset R, Nenzi M, Bracchi M, et al. COVID-19 in patients with HIV. Lancet HIV. 2020;7:e383.
20. Earnshaw VA, Smith LR, Chaudoir SR, et al. HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013;17:1785–1795.
21. Algarin AB, Varas-Rodríguez E, Valdivia C, et al. Symptoms, stress, and HIV-related care among older people living with HIV during the COVID-19 pandemic, Miami, Florida. AIDS Behav. 2020;17:1–3.
22. Kalichman SC, Eaton LA, Berman M, et al. Intersecting pandemics: impact of SARS-CoV-2 (COVID-19) protective behaviors on people living with HIV, atlanta, Georgia. J Acquir Immune Defic Syndr. 2020;85:66–72.
23. Clissoson K, Lee M, Gibbs A, et al. When home is not a safe place: impacts of social distancing directives on women living with HIV. AIDS Behav. 2020;24:3618–3620.
24. Roberts AL, Kubansky SD, Chibnik LB, et al. Association of post-traumatic stress and depressive symptoms with mortality in women. JAMA Netw Open. 2020;3:e2027935.
25. Shah S, Krause KD, Valera P, et al. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;24:2244–2249.
26. Joska JA, Andersen L, Rabie S, et al. COVID-19: increased risk to the mental health and safety of women living with HIV in South Africa. AIDS Behav. 2020;24:2751–2753.
27. MACS/WIHS Combined Cohort Study. MWCCS COVID Forms. 2020. Available at: https://mwccs.org/covid-forms/. Accessed August 31, 2020.
28. Schnurr P, Vielhauer M, Weathers F, et al. Brief Trauma Questionnaire. Washington D.C.: American Psychological Association; 1999.
29. Cameron RP, Gasman D. The primary care PTSD screen (PC-PTSD): development and operating characteristics. Prim Care Psychiatry. 2003;9:9–14.
30. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307.
31. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32:189–198.
32. Herrick A, Stall R, Egan J, et al. Pathways towards risk: syndemic conditions mediate the effect of adversity on HIV risk behaviors among young men who have sex with men (YMSM). J Urban Health. 2014;91:969–982.
33. Pantalone DW, Valentine SE, Woodward EN, et al. Syndemic indicators predict poor medication adherence and increased healthcare utilization for HIV-positive men who have sex with men. J Gay Lesbian Ment Health. 2018;22:71–87.
34. Biello KB, Colby D, Closson E, et al. The syndemic condition of psychosocial problems and HIV risk among male sex workers in Ho Chi Minh City, Vietnam. AIDS Behav. 2014;18:1264–1271.
35. Russell DW. UCLA loneliness scale (version 3): reliability, validity, and factor structure. J Pers Assess. 1996;66:20–40.
36. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385.
37. Radloff LS. The CES-D scale a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
38. Enders CK. The impact of nonnormality on full information maximum-likelihood estimation for structural equation models with missing data. Psychol Methods. 2001;6:352.
39. Theuninck AC, Lake N, Gibson S. HIV-related posttraumatic stress disorder: investigating the traumatic events. AIDS Patient Care STDS. 2010;24:485–491.
40. Mujumdar V, Pierson D, Briceño B, et al. Gathering trauma narratives: a qualitative study on the impact of self-identified traumas on people living with HIV (PLWH), North Carolina Med J. 2020;81:149–156.
41. Machtinger EL, Wilson TC, Haberer JE, et al. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16:2091–2100.
42. Tang C, Goldsamt L, Meng J, et al. Global estimate of the prevalence of post-traumatic stress disorder among adults living with HIV: a systematic review and meta-analysis. BMJ Open. 2020;10:e032435.
43. Young-Wolff KC, Sarovar V, Sterling SA, et al. Adverse childhood experiences, mental health, substance use, and HIV-related outcomes among persons with HIV. AIDS Care. 2019;31:1241–1249.
44. Fazeli PL, Waldrop-Valverde D, Yigit I, et al. An exploratory study of correlates of allostatic load in older people living with HIV. J Acquir Immune Defic Syndr. 2020;83:441–449.
45. Seedat S. Interventions to improve psychological functioning and health outcomes of HIV-infected individuals with a history of trauma or PTSD. Curr HIV AIDS Rep. 2012;9:344–350.
46. Ballivian J, Alcaide ML, Cecchini D, et al. Impact of COVID-19-related stress and lockdown on mental health among people living with HIV in Argentina. J Acquir Immune Defic Syndr. 2020;85:475–482.
47. Taylor CB, Fitzsimmons-Craft EE, Graham AK. Digital technology can catalyze for change. Int J Urban Health. 2020;44:132.
48. Meinert E, Rahman E, Potter A, et al. Acceptability and usability of the mobile digital health app NoObesity for families and health care professionals: protocol for a feasibility study. JMIR Res Protoc. 2020;9:e18068.
49. Bokolo Anthony J. Use of telemedicine and virtual care for remoteBJJ. 2020;44:143.2.
50. The Lancet Infectious D. The COVID-19 infodemic. J Acquir Immune Defic Syndr. 2020;20:875.